CKM Syndrome Prevalence and Its Association With SCORE-2 and BRI
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-79
SponsorUniversity of Gaziantep
About this trial
This cross-sectional study aims to determine the prevalence of Cardiovascular-Kidney-Metabolic (CKM) syndrome in a community-based adult population in Gaziantep, Türkiye. In addition to estimating the prevalence across CKM stages, the study investigates the associations between CKM syndrome and two key risk indicators: the SCORE-2 cardiovascular risk score and Body Roundness Index (BRI). Findings from this study will provide valuable insights into early cardiometabolic risk profiling and support the development of regionally tailored prevention strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
This observational study will include individuals aged 30 to 79 years who are registered at Bağlarbaşı Family Health Center, located in the Şahinbey district of Gaziantep, Türkiye. The study population represents a community-based sample receiving routine primary care services. Participants will be selected based on the availability of recent laboratory test results (within the past month) from the national Disease Management Platform (HYP). Anthropometric measurements will be obtained on-site. The population reflects a typical adult primary care population in an urban setting.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
No intervention is applied. This is a non-interventional, observational study. Anthropometric measurements and existing laboratory data are used for CKM staging and risk assessment.
Other interventionNo intervention is applied. This is a non-interventional, observational study. Anthropometric measurements and existing laboratory data are used for CKM staging and risk assessment.
Treatment groups
400 Participants
are divided into 1 treatment groupGroup A: 11 intervention
Trial outcomes
Primary outcomes
1
Prevalence of CKM Syndrome stages (0-4)
The proportion of participants classified into CKM Syndrome stages 0 to 4 based on AHA 2023 criteria, using clinical, biochemical, and anthropometric data.
Time frame
At the time of enrollment (single visit)Secondary outcomes
1
Association between CKM stages and SCORE-2 risk scores, BRI
Correlation analysis between CKM stages and BRI values derived from waist circumference and height. Evaluation of the relationship between CKM stage and 10-year cardiovascular risk estimated by SCORE-2 calculator, using ESC criteria for high-risk countries.
Time frame
At the time of enrollment (single visit)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: